摘要
目的比较术前新辅助同步放化疗与术前放疗治疗Ⅱ、Ⅲ期直肠癌的疗效。方法计算机检索Pub Med、中国期刊全文数据库、Cochrane系统评价数据库、Cochrane临床试验注册中心关于术前新辅助同步放化疗(放化疗组)与术前放疗(放疗组)治疗Ⅱ、Ⅲ期直肠癌肠癌疗效比较的文献。对纳入文献进行质量评价及数据提取,并进行Meta分析,比较新辅助同步放化疗与术前放疗的疗效。结果纳入研究的文献共7篇,患者2 928例。Meta分析结果显示:放化疗组与放疗组的3年及5年生存率、5年无病生存率、保肛率比较,差异无统计学意义(P>0.05);与放疗组比较,放化疗组局部复发降低率,根治性切除率、病理完全缓解率、病理降期率升高(P<0.05)。结论新辅助同步放化疗可作为Ⅱ/Ⅲ期直肠癌的术前治疗方案。
Objective To compare the efficacy of preoperative neoadjuvant concurrent chemoradiotherapy with preoperative radiotherapy for the treatment of stageⅡ/Ⅲ rectal cancer. Methods The databases of computer retrieve included PubMed, CNKI, Cochrane Database of Systematic Reviews ,and Cochrane Central Register of Controlled Trials. And the studies about the comparison of efficacy between preoperative neoadjuvant concurrent chemoradiotherapy （ chemoradiotherapy group ） and preoperative radiotherapy （ radiotherapy group ） for stage v rectal cancer were collected. The quality of included studies was assessed, and the data were collected. Then the Meta-analysis was performed to compare the efficacy of neoadjuvant concurrent chemoradiotherapy with that of preoperative radiotherapy. Results Seven studies were involved,which consisted of 2 928 patients. Meta-analysis showed that there was no significant difference in the 3/5-year survival rate, 5-year disease-free survival rate or rate of anal preservation between chemoradiotherapy group and radiotherapy group （ P 〉 0.05 ）. Compared to radiotherapy group ,the local recurrence rate decreased, the rate of radical excision, pathological complete remission rate and the rate of pathological down-staging elevated in the chemoradiotherapy group （ P 〈 0.05 ）. Condusion Neoadjuvant concurrent chemoradiotherapy is recommended as the preoperative therapy for stage Ⅱ/Ⅲ rectal cancer.
出处
《广西医学》
CAS
2016年第4期506-510,共5页
Guangxi Medical Journal
关键词
直肠癌
新辅助同步放化疗
疗效
系统评价
Rectal cancer, Neoadjuvant concurrent chemoradiotherapy, Efficacy, Systematic review
